Northwest Biotherapeutics Inc (NWBO)

0.55
0.02 3.18
NASDAQ : Health Care
Prev Close 0.57
Open 0.59
Day Low/High 0.55 / 0.60
52 Wk Low/High 0.46 / 12.49
Volume 1.09M
Avg Volume 2.20M
Exchange NASDAQ
Shares Outstanding 113.74M
Market Cap 70.52M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference In London

NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference In London

Dr. Marnix Bosch, Chief Technical Officer, Presented

NASDAQ Accepts NW Bio Remediation Plan For Shares and Warrants Previously Issued to Cognate BioServices

NASDAQ Accepts NW Bio Remediation Plan For Shares and Warrants Previously Issued to Cognate BioServices

Shares and Warrants To Be Cancelled and Reduced; MFN To Be Removed from Contracts

Short of Cash, Northwest Bio Flirts With Insolvency

Short of Cash, Northwest Bio Flirts With Insolvency

The cancer immunotherapy company's cash position has plunged to the point where it may no longer be capable of paying its operating expenses.

NW Bio Enters First 180-Day Grace Period Relating To Non-Compliance With Nasdaq $1.00 Per Share Bid Requirement

NW Bio Enters First 180-Day Grace Period Relating To Non-Compliance With Nasdaq $1.00 Per Share Bid Requirement

Progress Also Reported On Additional Nasdaq Compliance Issue

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.

NW Bio Announces Scientific Advisory Board

NW Bio Announces Scientific Advisory Board

Leading Experts in Immunotherapies and Oncology From Both the US and Europe

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

NW Bio Announces Operations Updates

NW Bio Announces Operations Updates

New Developments Relating to Phase I and II Trials, Scientific Advisory Board and Nasdaq Compliance

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

Biotech Stock Mailbag: Biomarin PKU Preview, Celldex Post-Mortem

TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stocks.

Northwest Bio Blames Short Sellers, Not Warning From Expert Doctor, for Stock Plunge

Northwest Bio Blames Short Sellers, Not Warning From Expert Doctor, for Stock Plunge

Frank comments and a warning from a doctor supervising pivotal brain cancer vaccine study for Northwest Bio are likely cause of sharp slide in stock price.

First Week of NWBO March 18th Options Trading

First Week of NWBO March 18th Options Trading

Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the March 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new March 18th contracts and identified the following put contract of particular interest.

NW Bio Issues Statement On Adverse Market Conditions And NW Bio Stock Decline

NW Bio Issues Statement On Adverse Market Conditions And NW Bio Stock Decline

Sees Impact of Global Market Concerns; Reiterates Encouraging Clinical Data

Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics

Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics

TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.

Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio

Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Northwest Bio Bothers British Bestie for Bounteous Bucks

Northwest Bio Bothers British Bestie for Bounteous Bucks

British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.